CUA Educational Content

Treatment Evolutions & Approaches in the Management  of Prostate Cancer: Bridging the Gap between Science and Patients

Editorial Committee: Fred Saad, Urban Emmenegger, Justin Lorentz


At the conclusion of this program, participants should be able to:

  • Recognize the DNA damage response (DDR) gene mutations that are involved in prostate cancer, and their implications for therapy
  • Integrate genetic testing for patients with prostate cancer into their clinical practice
  • Describe the mechanism of action, efficacy, and safety of PARP inhibitors in order to employ these agents for the treatment of prostate cancer with DDR mutations
  • Explain the timing, monitoring, and management of adverse events


This activity is an Accredited Self-Assessment Program (Section 3) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by the Canadian Urological Association. You may claim a maximum of 1 hour of credit.


​This program was made possible with financial support from AstraZeneca and Merck.